Creative Medical Technology Holdings, Inc. (CELZ) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$1.56M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$1.46M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$1.27M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.26M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$1.56M | (m) | (m) | (m) | (m) | -$1.47M* | (m) | $459.20K | $1.08M | $0.00 |
| 2026-03-31 | Reported | (m) | -$1.46M | (m) | (m) | (m) | (m) | -$1.32M | (m) | $541.66K | $888.64K | $0.00 |
| 2025-09-30 | Reported | (m) | -$1.27M | (m) | (m) | (m) | (m) | -$1.17M* | (m) | $465.15K | $776.82K | $0.00 |
| 2025-06-30 | Reported | (m) | -$1.26M | (m) | (m) | (m) | (m) | -$1.16M* | (m) | $501.26K | $731.52K | $0.00 |
| 2025-03-31 | Reported | (m) | -$1.66M | (m) | (m) | (m) | (m) | -$1.59M | (m) | $743.30K | $888.40K | $0.00 |
| 2024-09-30 | Reported | (m) | -$1.11M | (m) | (m) | (m) | (m) | -$985.59K* | (m) | $581.80K | $498.61K | $0.00 |
| 2024-06-30 | Reported | (m) | -$1.63M | (m) | (m) | (m) | (m) | -$1.47M* | (m) | $924.75K | $676.09K | $0.00 |
| 2024-03-31 | Reported | (m) | -$1.12M | (m) | (m) | (m) | (m) | -$896.86K | (m) | $422.39K | $671.48K | $0.00 |
| 2023-09-30 | Reported | (m) | -$1.54M | (m) | (m) | (m) | (m) | -$1.30M* | (m) | $992.72K | $531.04K | $0.00 |
| 2023-06-30 | Reported | (m) | -$1.19M | (m) | (m) | (m) | (m) | -$986.74K* | (m) | $309.48K | $859.54K | $0.00 |
| 2023-03-31 | Reported | (m) | -$1.11M | (m) | (m) | (m) | (m) | -$3.84M | (m) | $319.03K | $771.02K | $0.00 |
| 2022-09-30 | Reported | (m) | -$1.02M | (m) | (m) | (m) | (m) | -$873.30K* | (m) | $230.94K | $805.46K | $0.00 |
| 2022-06-30 | Reported | (m) | -$1.79M | (m) | (m) | (m) | (m) | -$1.76M* | (m) | $659.70K | $1.11M | $0.00 |
| 2022-03-31 | Reported | (m) | -$1.15M | (m) | (m) | (m) | (m) | -$1.58M | (m) | $10.00K | $1.13M | $0.00 |
| 2021-09-30 | Reported | (m) | -$833.44K | (m) | (m) | (m) | (m) | -$390.79K* | (m) | $59.18K | $757.24K | $0.00 |
| 2021-06-30 | Reported | (m) | -$515.84K | (m) | (m) | (m) | (m) | -$222.14K* | (m) | $0.00 | $498.32K | (m) |
| 2021-03-31 | Reported | (m) | -$303.94K | (m) | (m) | (m) | (m) | -$441.52K | (m) | $0.00 | $280.92K | $0.00 |
| 2020-09-30 | Reported | (m) | -$242.47K | (m) | (m) | (m) | (m) | -$174.01K* | (m) | $0.00 | $285.10K | $0.00 |
| 2020-06-30 | Reported | (m) | -$214.26K | (m) | (m) | (m) | (m) | -$122.21K* | (m) | (m) | $214.89K | (m) |
| 2020-03-31 | Reported | (m) | -$335.04K | (m) | (m) | (m) | (m) | -$195.32K | (m) | (m) | $346.17K | $0.00 |
| 2019-09-30 | Reported | (m) | -$273.42K | (m) | (m) | (m) | (m) | -$358.28K* | (m) | $0.00 | $317.64K | $0.00 |
| 2019-06-30 | Reported | (m) | -$275.46K | (m) | (m) | (m) | (m) | -$329.37K* | (m) | $0.00 | $312.57K | $0.00 |
| 2019-03-31 | Reported | (m) | -$250.70K | (m) | (m) | (m) | (m) | -$273.01K | (m) | $0.00 | $281.97K | $0.00 |
| 2018-09-30 | Reported | (m) | -$274.83K | (m) | (m) | (m) | (m) | -$346.94K* | (m) | $2.88K | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$314.83K | (m) | (m) | (m) | (m) | -$244.76K* | (m) | $4.20K | (m) | $0.00 |
| 2018-03-31 | Reported | (m) | -$204.22K | (m) | (m) | (m) | (m) | -$164.94K | (m) | $3.20K | (m) | $0.00 |
| 2017-09-30 | Reported | (m) | -$295.00K | (m) | (m) | (m) | (m) | -$273.68K* | (m) | $87.73K | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$395.99K | (m) | (m) | (m) | (m) | -$269.47K* | (m) | $25.19K | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$240.85K | (m) | (m) | (m) | (m) | -$223.75K | (m) | $59.83K | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$212.54K | (m) | (m) | (m) | (m) | (m) | (m) | $45.17K | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$209.25K | (m) | (m) | (m) | (m) | (m) | (m) | $18.03K | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$147.84K | (m) | (m) | (m) | (m) | $0.00 | (m) | $4.36K | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$3.73K | (m) | (m) | (m) | (m) | -$2.40K* | (m) | (m) | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$3.77K | (m) | (m) | (m) | (m) | -$4.94K* | (m) | (m) | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$6.99K | (m) | (m) | (m) | (m) | -$5.37K | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$3.55K | (m) | (m) | (m) | (m) | -$2.65K* | (m) | (m) | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$3.63K | (m) | (m) | (m) | (m) | -$5.25K* | (m) | (m) | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$8.04K | (m) | (m) | (m) | (m) | -$4.08K | (m) | (m) | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$3.60K | (m) | (m) | (m) | (m) | -$3.68K* | (m) | (m) | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$3.99K | (m) | (m) | (m) | (m) | -$5.89K* | (m) | (m) | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$8.45K | (m) | (m) | (m) | (m) | -$9.03K | (m) | (m) | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$4.08K | (m) | (m) | (m) | (m) | -$3.98K* | (m) | (m) | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$3.69K | (m) | (m) | (m) | (m) | -$2.60K* | (m) | (m) | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$7.81K | (m) | (m) | (m) | (m) | -$6.97K | (m) | (m) | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$3.50K | (m) | (m) | (m) | (m) | -$5.20K* | (m) | (m) | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$3.45K | (m) | (m) | (m) | (m) | -$4.91K* | (m) | (m) | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$7.27K | (m) | (m) | (m) | (m) | -$3.75K | (m) | (m) | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$2.77K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$6.14M | (m) | (m) | (m) | (m) | -$5.86M | (m) | $2.26M | $3.76M | $0.00 |
| 2024-12-31 | Reported | (m) | -$5.74M | (m) | (m) | (m) | (m) | -$5.30M | (m) | $2.40M | $3.24M | $0.00 |
| 2023-12-31 | Reported | (m) | -$5.62M | (m) | (m) | (m) | (m) | -$8.03M | (m) | $1.97M | $3.56M | $0.00 |
| 2022-12-31 | Reported | (m) | -$10.24M | (m) | (m) | (m) | (m) | -$7.80M | (m) | $6.27M | $3.94M | $0.00 |
| 2021-12-31 | Reported | (m) | -$3.13M | (m) | (m) | (m) | (m) | -$2.22M | (m) | $109.18K | $2.96M | $0.00 |
| 2020-12-31 | Reported | (m) | -$1.11M | (m) | (m) | (m) | (m) | -$434.56K | (m) | $0.00 | $1.16M | $0.00 |
| 2019-12-31 | Reported | (m) | -$1.13M | (m) | (m) | (m) | (m) | -$1.21M | (m) | $0.00 | $1.22M | $0.00 |
| 2018-12-31 | Reported | (m) | -$1.11M | (m) | (m) | (m) | (m) | -$1.05M | (m) | $96.62K | $1.05M | $0.00 |
| 2017-12-31 | Reported | (m) | -$1.18M | (m) | (m) | (m) | (m) | -$889.62K | (m) | $260.08K | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$759.67K | (m) | (m) | (m) | (m) | -$445.23K | (m) | $85.33K | (m) | $0.00 |
| 2015-12-31 | Reported | (m) | -$20.83K | (m) | (m) | (m) | (m) | -$14.64K | (m) | (m) | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$19.43K | (m) | (m) | (m) | (m) | -$17.32K | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$20.12K | (m) | (m) | (m) | (m) | -$22.91K | (m) | (m) | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$20.10K | (m) | (m) | (m) | (m) | -$16.77K | (m) | (m) | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$19.83K | (m) | (m) | (m) | (m) | -$13.96K | (m) | (m) | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$14.29K | (m) | (m) | (m) | (m) | -$13.66K | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |